Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038362 (
stomatitis
)
8,852
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
FLN29
was identified as an interferon (IFN)-inducible gene, and it has been shown to suppress Toll-like receptor 4-mediated NF-kappaB activation by binding to TRAF6. To elucidate the physiological roles of
FLN29
, we generated
FLN29
-deficient mice.
FLN29
deficiency resulted in hyper-response to LPS both in vivo and in vitro, demonstrating the negative regulatory role of
FLN29
in TLR4 signaling. Furthermore, we found that
FLN29
(-/-) mice exhibited increased susceptibility to poly(I:C)-induced septic shock compared with WT mice.
FLN29
(-/-) fibroblasts were highly resistant to vesicular
stomatitis
virus infection, and these cells produced more IFN-beta than WT cells did in response to not only intracellular poly(I:C) but also overexpression of IPS-1. Forced expression of
FLN29
inhibited the IPS-1-dependent activation of both NF-kappaB and IRF3. We also found that
FLN29
could interact with TRIF, IPS-1, TRAF3, and TRAF6. Together, these results suggest that
FLN29
, in addition to playing a negative regulatory role in the TLR4 signaling pathway, negatively regulates the RIG-I-like helicase signaling pathway at the level of IPS-1/TRAF6 and IPS-1/TRAF3 complexes.
...
PMID:FLN29 deficiency reveals its negative regulatory role in the Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like helicase signaling pathway. 1884 41